Stay updated on GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check4 days agoChange DetectedAdded a Locations section with California, Colorado, Florida, Illinois, Kentucky, Louisiana, New Hampshire, and Virginia; removed HHS Vulnerability Disclosure and the listed state location sections, and updated the revision to v3.3.3.SummaryDifference1.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now shows Revision: v3.3.2, replacing the previous v3.2.0. No study-specific information appears to be changed.SummaryDifference0.1%

- Check41 days agoChange DetectedA government funding status notice on the page was removed. This change does not affect any study details, eligibility criteria, or results reporting; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check62 days agoChange DetectedNo substantive changes detected to the Study Details page for NCT03417882; core sections like eligibility criteria, study design, and participating locations appear unchanged.SummaryDifference0.5%

- Check84 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference3%

- Check91 days agoChange DetectedUpdated the page to reflect a new version (v3.1.0) and removed the old version tag (v3.0.2).SummaryDifference0.1%

Stay in the know with updates to GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.